JavaScript is disabled. Please enable to continue!
News & Events >> Press Releases >> Laboratory extension in Dungarvan

Eurofins BioPharma Product Testing Ireland, Ltd., opens state-of-the-art laboratory extension in Dungarvan

Sidebar Image

Tuesday, October 2, 2018

Dungarvan ExtensionEurofins BioPharma Product Testing Ireland, Ltd. today opened the new extension to its laboratory facility in Dungarvan, Co Waterford. The company is located in the IDA Business Park, where the new laboratory extension expands the previously 4,300m2 facility by an additional 4,400m2, more than doubling the facility footprint and thereby providing increased capacity that will support the continued enhancement of the services offered to its clients and the ongoing growth of the business.

The company is part of the Eurofins Group and focuses on analytical testing to support the development of new medicines by pharmaceutical and biopharmaceutical companies. The work done at the Dungarvan laboratories provides important insights that further the development of safe, effective medication to help manage infections and cure disease. The new extension will primarily house the Bioanalytics and Molecular Cell Biology departments, in particular introducing new technologies such as Bioassay[1], ELISA[2] and qPCR[3]. All of these will offer clients increased flexibility within the Eurofins network, as key testing capabilities are now all available at one site.

The construction of the new facility started in mid-August 2017 and Eurofins BioPharma Product Testing worked with Waterford-based construction company Tom O’Brien Construction, who carried out the work. Approximately 50 construction staff were on site each day, including the main contractor and subcontractors, with approximately 2,000 work hours per week carried out over the total of 13 months’ construction phase. The new laboratory boasts the latest in laboratory equipment, enabling the highly skilled staff to work with the most modern instruments and technologies, in order to provide fast, accurate information for their customers.

Eurofins’ BioPharma Product Testing Managing Director Carmel Fitzpatrick said: “The opening of the new laboratory extension today marks an important milestone in our company’s long history. For over 30 years, we have supported the pharmaceutical and biopharmaceutical industry in its work to develop new medication to improve health and well-being, most recently as part of the Eurofins Group. The investment into new laboratory space is a reflection of the increased demands of our customers and at the same time testament to the positive impact the dedication and hard work of our staff have made. I am looking forward to welcoming many new colleagues to our new facility, in order to provide the continuously high standard of testing and results to our growing client base.”

IDA Ireland Executive Director Mary Buckley congratulated Eurofins on the opening of their new laboratory extension, saying: “It’s great to see Eurofins add considerable value to their existing site with this new state-of-the-art laboratory extension, which will allow them to greatly increase their capacity. It’s an important strategic step in the future development of a company that has been innovative and dynamic in the field of analytical testing in support of the biopharma sector. This is a clear demonstration of its continued commitment to Dungarvan and Waterford. Eurofins has contributed substantially to the local economy as one of the biggest employers in the SE region and that they are seeking to hire additional employees at this time is great news. I wish Carmel and her team in Dungarvan continued success.”

Eurofins Biopharma Product Testing is already one of the major local employers in the region, employing 250 staff on site and an additional 250 staff located within clients’ facilities. With today’s opening of the lab extension, the company is looking to hire additional employees across a number of departments including, Microbiology, Pharmaceutical Chemistry, Biochemistry and their bespoke Professional Scientific Services (PSS) programme. In addition, there are opportunities in various support functions as well as attractive managerial positions for which the company is now hiring.

In order to attract the right candidates, who are interested in bringing their dedication and expertise to Eurofins, the company is holding an Open Day on 13th October. Those interested in attending this event with a view to joining the Eurofins team are invited to register their attendance by e-mailing MyFuture@eurofins.com by 5 October.

Eurofins BioPharma Testing in Dungarvan, is a member of Eurofins BioPharma Product Testing Group — the largest network of harmonised bio/pharmaceutical GMP product testing laboratories worldwide. Its parent company, Eurofins Scientific employs over 38,000 staff in over 400 laboratories across 44 countries. 

Notes for the editor:

Eurofins a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 38,000 staff in 400 laboratories across 44 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

For further information visit: http://eurofins.com

 

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.

Press contact:

Daniela Karthaus

Group Head of Communication

Phone: +353 – 87 937 5305

danielakarthaus@eurofins.ie

 

[1] Bioassay refers to an analytical method to measure the potency of a substance by its effect on tissues. This is an important part of the discovery of new medicines.

[2] ELISA (enzyme-linked immunosorbent assay) is a commonly used analytical biochemistry test, detecting for example the presence of antigens or antibodies. This is often used to detect HIV or the West Nile Virus, but ELISA also plays a huge role as a quality-control check in a number of industries, including the pharmaceutical and biopharmaceutical industry.

[3] qPCR stands for quantitative polymerase chain reaction. This is a laboratory technique which monitors the amplification of a targeted DNA, which among other uses can help to detect infectious diseases, cancer and genetic abnormalities.